Text

Analisis Kadar Mangiferin dalam Kitosan-Alginat Nanopartikel di Hati Tikus pada Fase Absorpsi dan Fase Eliminasi = Analysis of Mangiferin Levels in Chitosan-Alginate Nanoparticles in Rat Livers in the Absorption and Elimination Phases.

Latar belakang: Mangiferin merupakan metabolit bioaktif polifenol yang berasal dari Mangifera indica L. dengan potensinya sebagai kelator besi, antioksidan, antidiabetes, antiinflamasi, antitumor, dan immunomodulator. Namun, absorpsi yang rendah dan bioavailabilitas yang kecil menyebabkan mangiferin tidak cukup untuk memberikan efek terapi sehingga nanopartikel diharapkan dapat menjadi solusinya. Metode: Studi ini menggunakan dua kelompok yaitu tikus Sprague Dawley dengan pemberian mangiferin konvensional dan mangiferin yang dikemas dalam nanopartikel kitosan-alginat dengan dosis 50 mg/kgBB. Pengukuran kadar mangiferin di organ hati tikus dilakukan pada fase absorpsi (jam ke-3) dan fase eliminasi (jam ke-5½). Kadar mangiferin yang terhitung terdapat di dalam homogenat organ hati tikus. Analisis kadar mangiferin menggunakan high performance liquid chromatography (HPLC). Hasil dan pembahasan: Hasil pengukuran kadar mangiferin pada fase absorpsi di hati menunjukkan bahwa tidak ada perbedaan signifikan (p = 0,153) antara kedua kelompok. Sementara itu, hasil pengukuran kadar mangiferin pada fase eliminasi di hati menunjukkan adanya peningkatan sebesar 78,39% pada kelompok mangiferin kitosanalginat nanopartikel (p = 0,000). Perbedaan proses farmakokinetik antara fase absorpsi dan fase eliminasi menjadi penyebab dari perbedaan hasil tersebut. Kesimpulan: Kadar mangiferin kitosan-alginat nanopartikel di organ hati mengalami kecenderungan peningkatan sebesar 39,75% pada fase absorpsi dibandingkan kadar mangiferin konvensional, sedangkan kadar mangiferin kitosan-alginat nanopartikel di organ hati meningkat sebesar 78,39% pada fase eliminasi dibandingkan kadar mangiferin konvensional.
Kata kunci: mangiferin, nanopartikel, kitosan-alginat, hati


Background: Mangiferin is a polyphenol bioactive metabolite derived from Mangifera indica L. with potential as an iron chelator, antioxidant, antidiabetic, anti-inflammatory, antitumor, and immunomodulator. However, its low absorption and small bioavailability cause mangiferin to be insufficient to provide a therapeutic effect so that nanoparticles are expected to be the solution. Methods: This study used two groups that consist of Sprague Dawley rats were given conventional mangiferin and Sprague Dawley rats given chitosan-alginate mangiferin with a dose of 50 mg/kgBW. Measurement of mangiferin in the liver of rats was carried out in the absorption phase (3 hours after administration) and elimination phase (5½ hours after administration). Mangiferin levels were measured from the rat liver homogenate. Analysis of mangiferin levels using high performance liquid chromatography (HPLC). Results and discussion: There were no significant difference (p = 0.153) between the two forms of mangiferin in the absorption phase. Meanwhile, there was a significant increase of 78,39% in the chitosan-alginate mangiferin compared to the conventional mangiferin (p = 0.000) in the elimination phase. The difference in pharmacokinetic processes between the two phases becomes reason for the difference in results. Conclusion: The levels of chitosan-alginate nanoparticle mangiferin in the liver tended to increase by 39.75% in the absorption phase compared to the conventional mangiferin, while the levels of chitosan-alginate nanoparticle mangiferin in the liver increased by 78.39% in the elimination phase compared to the conventional mangiferin.
Keywords: mangiferin, nanoparticle, chitosan-alginate, liver